Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach.

Internal and Emergency Medicine
Jeanne de La RochefoucauldOlivier Lambotte

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. The number of indications is increasing and antibodies targeting the CTLA-4 and PD-1/PD-L1 pathways are now also prescribed in adjuvant settings and for metastatic cancer. However, ICIs reactivate autoreactive immune cells as well as tumour-specific T cells, which lead to immune-related adverse events (irAEs) in around 70% of treated patients. Although all organs can potentially be involved, the skin, gut, thyroid, lungs, liver, and joints are most frequently affected. Most irAEs occur in the first few months of treatment but late-onset toxicity-even after the ICI has been discontinued-is also possible. In terms of severity, most irAEs are grade 1-2. Some irAEs (especially myocarditis, pneumonitis, and encephalitis) are potentially fatal; in patients with highly suggestive clinical signs, treatment should be initiated before the diagnostic work-up has been completed. When confronted with an unexpected clinical sign, the physician must differentiate rapidly between an irAE, cancer progression, and another (unrelated) cause. The management of irAEs is based on the temporary or permanent discontinuation of the ICI and (for grade ≥ 2 events) the administratio...Continue Reading

References

Jul 4, 2007·International Immunology·Taku Okazaki, Tasuku Honjo
Jul 10, 2009·The New England Journal of Medicine·Fouad FadelBertrand Knebelmann
Oct 23, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel S ChenF Stephen Hodi
Dec 25, 2012·Current Oncology Reports·Patricia A Tang, Daniel Y C Heng
Jun 19, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anupa SharmaJanice M Mehnert
Jan 22, 2014·Nature Reviews. Clinical Oncology·Tara C Gangadhar, Robert H Vonderheide
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Dec 31, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S ChampiatA Marabelle
Feb 15, 2016·Cancer Treatment Reviews·Lavinia SpainJames Larkin
Apr 5, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V R BelumM E Lacouture
Jun 11, 2016·Kidney International·Frank B CortazarDavid E Leaf
Nov 3, 2016·The New England Journal of Medicine·Douglas B JohnsonJavid J Moslehi
Jan 7, 2017·Current Opinion in Oncology·Jordi Remon, Benjamin Besse
Jan 9, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S CuzzubboA F Carpentier
Jan 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberCaroline Robert
Feb 20, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ralf GutzmerUNKNOWN German Dermatooncology Group (DeCOG)
Feb 28, 2017·Journal for Immunotherapy of Cancer·Eileen ShiuanDouglas Johnson
Mar 10, 2017·Expert Review of Anticancer Therapy·Omar Abdel-RahmanAnwar Giryes
Jun 19, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alice Bernard-TessierJean-Marie Michot
Jun 25, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sébastien Le BurelOlivier Lambotte
Jul 28, 2017·American Journal of Clinical Oncology·Brandon M HuffmanSvetomir N Markovic
Aug 24, 2017·International Journal of Cancer. Journal International Du Cancer·Yingcheng WuHuiqun Wu
Sep 5, 2017·Annals of Internal Medicine·Dimitri ArangalageCéleste Lebbé
Sep 12, 2017·The New England Journal of Medicine·Jeffrey WeberUNKNOWN CheckMate 238 Collaborators
Sep 19, 2017·Journal of the American Academy of Dermatology·Julia DaiMario E Lacouture
Nov 12, 2017·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Qiang ChenHong-Bin Liu
Dec 20, 2017·American Journal of Clinical Dermatology·Vincent Sibaud
Jan 11, 2018·The New England Journal of Medicine·Michael A PostowMatthew D Hellmann
Jan 18, 2018·Muscle & Nerve·Noah A KolbMike Hehir
Feb 11, 2018·Journal of Hepatology·Eleonora De MartinDidier Samuel
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerUNKNOWN National Comprehensive Cancer Network
Mar 15, 2018·Lancet·Javid J MoslehiDouglas B Johnson
Mar 24, 2018·Journal of the American College of Cardiology·Syed S MahmoodTomas G Neilan
Jun 20, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.